Waltham, MA – According to filings with the U.S. Securities and Exchange Commission, Nocion Therapeutics is raising $16,999,993.00 in new funding. Sources indicate as part of senior management President and Chief Operating Officer, Rick Batycky played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Nocion Therapeutics
Nocion Therapeutics is a biopharmaceutical company developing novel treatments for silencing neurons. The company’s platform of unique molecular entities selectively affects inflamed nociceptors. Treatment using this approach aims to provide more durable and robust local analgesic effects while minimizing numbness or paralysis and other systemic off-target effects. The company’s mission is to safely alleviate suffering for millions of patients with conditions arising from activated sensory neurons including chronic cough, pain and itch.

To learn more about Nocion Therapeutics, visit http://www.nociontx.com/

Contact:
Rick Batycky, President and Chief Operating Officer
781-819-2877
https://www.linkedin.com/in/rick-batycky-221a7011/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved